Pfizer buying hematology company Global Blood Therapeutics
1 min read
<
Pfizer Inc.’s top-selling COVID-19 vaccine and treatment left the company flush with cash to spend on acquisitions.
NEW YORK — Pfizer will spend about $5.4 billion to buy Global Blood Therapeutics as the pharmaceutical giant continues to invest some of the cash influx reaped during the COVID-19 pandemic.
Pfizer said Monday that the acquisition will boost its capabilities in rare hematology. Global Therapeutics makes Oxybryta tablets for treating sickle cell disease.
The latest deal follows Pfizer’s $11.6 billion acquisition of Biohaven, which the companies announced in May, and a $6.7 billion acquisition of Arena Pharmaceuticals announced last December.
…
2022-08-08 06:35:49
All news and articles are copyrighted to the respective authors and/or News Broadcasters. RockyDailyNews.Com is an independent Online News Aggregator
Read more from original source here…